These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 25547018)

  • 21. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
    Yuan Y; Trivedi D; Maclean R; Rosenblatt L
    J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
    Tanno M; Nakamura I; Ito K; Tanaka H; Ohta H; Kobayashi M; Tachihara A; Nagashima M; Yoshino S; Nakajima A
    Mod Rheumatol; 2006; 16(2):77-84. PubMed ID: 16633926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
    Bansback NJ; Brennan A; Ghatnekar O
    Ann Rheum Dis; 2005 Jul; 64(7):995-1002. PubMed ID: 15550533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis.
    Patel D; Shelbaya A; Cheung R; Aggarwal J; Park SH; Coindreau J
    Adv Ther; 2019 Aug; 36(8):2086-2095. PubMed ID: 31148057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G; Lindgren P; Singh A; Klareskog L
    Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
    Davies A; Cifaldi MA; Segurado OG; Weisman MH
    J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA; Foster RH
    Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.
    Stevenson MD; Wailoo AJ; Tosh JC; Hernandez-Alava M; Gibson LA; Stevens JW; Archer RJ; Simpson EL; Hock ES; Young A; Scott DL
    J Rheumatol; 2017 Jul; 44(7):973-980. PubMed ID: 28202743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
    Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
    Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
    Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
    Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T;
    Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.
    Kobelt G; Jönsson L; Young A; Eberhardt K
    Rheumatology (Oxford); 2003 Feb; 42(2):326-35. PubMed ID: 12595631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China.
    Tian L; Xiong X; Guo Q; Chen Y; Wang L; Dong P; Ma A
    Pharmacoeconomics; 2020 Dec; 38(12):1345-1358. PubMed ID: 32929677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis.
    Peng K; Chan SCW; Wang Y; Cheng FWT; Yeung WWY; Jiao Y; Chan EWY; Wong ICK; Lau CS; Li X
    JAMA Netw Open; 2024 Jun; 7(6):e2418800. PubMed ID: 38922614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of biological therapy compared with methotrexate in the treatment for rheumatoid arthritis in Colombia.
    Valle-Mercado C; Cubides MF; Parra-Torrado M; Rosselli D
    Rheumatol Int; 2013 Dec; 33(12):2993-7. PubMed ID: 23907586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.
    Iannazzo S; Benucci M; Favalli EG
    Clin Exp Rheumatol; 2018; 36(3):479-485. PubMed ID: 29352843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients.
    Tian F; Li JY; Wen ZH; Luo XW; Deng L; Zhang L; He JY
    Medicine (Baltimore); 2019 Nov; 98(48):e17750. PubMed ID: 31770193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.